替尔泊肽同靶点药物获批临床试验 智飞生物股价盘中涨超6%

Core Viewpoint - The stock price of Zhifei Biological surged over 6% following the announcement of clinical trial approval for its CA111 injection, a dual agonist targeting GIP and GLP-1 receptors, indicating potential growth in the obesity treatment market [1]. Group 1: Company Developments - Zhifei Biological's subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1]. - CA111 injection is noted as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with no other domestic products targeting the same receptors approved for market as of the announcement date [1]. Group 2: Market Impact - The approval of the clinical trial for CA111 injection is not expected to have a significant impact on the company's recent performance but is seen as beneficial for strengthening the company's research and development capabilities and pipeline reserves [1].